Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.52 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL575045 | 1.00 | AKR1C3 (0.57) | AKR1C3AKR1C2SMN1; SMN2CFTRSLC6A2 | |
| SCHEMBL27446830 | 0.98 | AKR1C3 (0.56) | AKR1C3AKR1C2SMN1; SMN2CFTRSLC6A2 | |
| Hydrochloric Acid SCHEMBL4076278 | 0.98 | AKR1C3 (0.56) | AKR1C3AKR1C2SMN1; SMN2CFTRSLC6A2 | |
| SCHEMBL22899009 | 0.89 | CYP19A1 (0.51) | AKR1C3AKR1C2SMN1; SMN2CFTRSLC6A2 | |
| SCHEMBL27492286 | 0.86 | CYP19A1 (0.52) | AKR1C3AKR1C2SMN1; SMN2CFTRSLC6A2 | |
| Pyridine SCHEMBL28233602 | 0.85 | SMN1; SMN2 (0.50) | AKR1C3AKR1C2SMN1; SMN2CFTRSLC6A2 | |
| SCHEMBL9484991 | 0.84 | NAPRT (0.53) | AKR1C3AKR1C2SMN1; SMN2CYP19A1TBXAS1 | |
| SCHEMBL17233832 | 0.83 | CYP17A1 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30159419 | 0.83 | CYP17A1 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17233924 | 0.83 | CYP17A1 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1212197-C | Catalytic system used for homogeneous hydroxylation reaction and its manufacturing method and application | CHINESE ACAD INST CHEMISTRY (CN) | 2005-07-27 | — | — | CN | claimed |
| WO-2004089357-A2 | ANTI-FUNGAL FORMULATION OF TRITERPENE AND ESSENTIAL OIL | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2004-10-21 | — | — | WO | claimed |
| CN-1517150-A | Catalytic system used for homogeneous hydroxylation reaction and its manufacturing method and application | 中国科学院化学研究所 | 2004-08-04 | — | — | CN | claimed |
| US-20260022143-A1 | Cyclic Peptide Inhibitors of IL-23 | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-22 | — | — | US | disclosed |
| CN-120035578-A | Sulfonamide compound, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119751456-A | Spiro compounds | C4医药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-112312904-B | Spiro compounds | C4医药公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240425528-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | PROTOMER TECH INC (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2024240056-A1 | SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| US-12139502-B2 | Aromatic boron-containing compounds and related insulin analogs | PROTOMER TECHNOLOGIES INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-1212197-C | Catalytic system used for homogeneous hydroxylation reaction and its manufacturing method and application | CHINESE ACAD INST CHEMISTRY (CN) | 2005-07-27 | — | — | CN | disclosed |
| WO-2004089357-A2 | ANTI-FUNGAL FORMULATION OF TRITERPENE AND ESSENTIAL OIL | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2004-10-21 | — | — | WO | disclosed |
| CN-1517150-A | Catalytic system used for homogeneous hydroxylation reaction and its manufacturing method and application | 中国科学院化学研究所 | 2004-08-04 | — | — | CN | disclosed |
| CN-1085980-C | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 2002-06-05 | — | — | CN | disclosed |
| CN-1042031-C | Novel quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental | PROCTER & GAMBLE PHARMA (US) | 1999-02-10 | — | — | CN | disclosed |
| CN-1201454-A | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 1998-12-09 | — | — | CN | disclosed |
| CN-1130898-A | Difluorostone antiviral analogs | MERRELL DOW PHARMA (US) | 1996-09-11 | — | — | CN | disclosed |
| CN-1126988-A | Difluoro statone analogs | MERRELL DOW PHARMA (US) | 1996-07-17 | — | — | CN | disclosed |
| CN-1088213-A | Contain the quaternary nitrogen phosphinic acid compounds, pharmaceutical composition and treatment calcium and the unusual method of phosphate metabolism and treatment prevention tartar and dental plaque method | PROCTER & GAMBLE PHARMA (US) | 1994-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022143-A1 | Cyclic Peptide Inhibitors of IL-23 | IL23R, IL17A, IL36G | AKR1C3 1618/4885AKR1C2 2274/4885SMN1; SMN2 2640/4885 |
| US-20240425528-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | IAPP, GPR119, INSR | AKR1C3 1171/4885AKR1C2 851/4885SMN1; SMN2 775/4885 |
| US-12139502-B2 | Aromatic boron-containing compounds and related insulin analogs | IAPP, GPR119, INSR | AKR1C3 1171/4885AKR1C2 851/4885SMN1; SMN2 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.